Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Maze Therapeutics (MAZE) Profit After Tax (2024 - 2026)

Maze Therapeutics' Profit After Tax history spans 3 years, with the latest figure at -$24.2 million for Q1 2026.

  • On a quarterly basis, Profit After Tax rose 26.16% to -$24.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$122.5 million, a 335.93% decrease, with the full-year FY2025 number at -$131.1 million, down 351.04% from a year prior.
  • Profit After Tax hit -$24.2 million in Q1 2026 for Maze Therapeutics, up from -$34.6 million in the prior quarter.
  • Over the last five years, Profit After Tax for MAZE hit a ceiling of $139.1 million in Q2 2024 and a floor of -$34.6 million in Q4 2025.
  • Historically, Profit After Tax has averaged -$11.5 million across 3 years, with a median of -$30.1 million in 2025.
  • Biggest five-year swings in Profit After Tax: plummeted 124.22% in 2025 and later increased 26.16% in 2026.
  • Tracing MAZE's Profit After Tax over 3 years: stood at -$29.6 million in 2024, then decreased by 16.87% to -$34.6 million in 2025, then rose by 29.97% to -$24.2 million in 2026.
  • Business Quant data shows Profit After Tax for MAZE at -$24.2 million in Q1 2026, -$34.6 million in Q4 2025, and -$30.1 million in Q3 2025.